What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Myocardial infarction
- Cardiology
His scientific interests lie mostly in Internal medicine, Myocardial infarction, Cardiology, Surgery and Acute coronary syndrome.
Frans Van de Werf combines subjects such as Stroke and Heart failure with his study of Myocardial infarction.
His Stroke study combines topics from a wide range of disciplines, such as Anesthesia, Streptokinase, Aspirin and Clinical endpoint.
As part of the same scientific family, Frans Van de Werf usually focuses on Cardiology, concentrating on Fibrinolytic agent and intersecting with Tenecteplase and Survival rate.
The study incorporates disciplines such as Placebo, Tissue plasminogen activator and Risk factor in addition to Surgery.
Frans Van de Werf interconnects Mortality rate, Emergency medicine, Clopidogrel, Severity of illness and Angina in the investigation of issues within Acute coronary syndrome.
His most cited work include:
- An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. (3240 citations)
- Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. (2080 citations)
- Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both (2012 citations)
What are the main themes of his work throughout his whole career to date?
Frans Van de Werf mainly focuses on Internal medicine, Cardiology, Myocardial infarction, Surgery and Acute coronary syndrome.
His work on Percutaneous coronary intervention, ST segment, Thrombolysis and Conventional PCI is typically connected to In patient as part of general Internal medicine study, connecting several disciplines of science.
Many of his studies involve connections with topics such as Hazard ratio and Cardiology.
His Myocardial infarction study combines topics in areas such as Stroke, Fibrinolytic agent and Randomized controlled trial.
His research investigates the connection between Randomized controlled trial and topics such as Clinical trial that intersect with problems in Intensive care medicine.
His studies in Acute coronary syndrome integrate themes in fields like Platelet aggregation inhibitor and Clopidogrel.
He most often published in these fields:
- Internal medicine (69.46%)
- Cardiology (63.52%)
- Myocardial infarction (43.54%)
What were the highlights of his more recent work (between 2012-2021)?
- Internal medicine (69.46%)
- Cardiology (63.52%)
- Myocardial infarction (43.54%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Cardiology, Myocardial infarction, Acute coronary syndrome and Percutaneous coronary intervention.
His Stroke, ST segment, Hazard ratio, Vorapaxar and Heart failure study are his primary interests in Internal medicine.
His work on TIMI, Ticagrelor and Coronary artery disease as part of general Cardiology study is frequently linked to In patient, therefore connecting diverse disciplines of science.
The Myocardial infarction study combines topics in areas such as Fibrinolysis, Fibrinolytic agent and Surgery.
His Acute coronary syndrome research is multidisciplinary, incorporating elements of Platelet aggregation inhibitor, Observational study, Clinical trial, Revascularization and Prospective cohort study.
His Percutaneous coronary intervention study combines topics in areas such as Reperfusion therapy, Cardiogenic shock, Stent, Infarction and Electrocardiography.
Between 2012 and 2021, his most popular works were:
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes (1573 citations)
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). (1195 citations)
- Dabigatran versus Warfarin in Patients with Mechanical Heart Valves (844 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Myocardial infarction
- Cardiology
Internal medicine, Myocardial infarction, Cardiology, Acute coronary syndrome and Percutaneous coronary intervention are his primary areas of study.
His research on Internal medicine frequently connects to adjacent areas such as Surgery.
Frans Van de Werf combines subjects such as Fibrinolytic agent, Confidence interval and Emergency medicine with his study of Myocardial infarction.
The various areas that Frans Van de Werf examines in his Cardiology study include Clinical endpoint and Randomized controlled trial.
His Acute coronary syndrome research incorporates themes from Platelet aggregation inhibitor, Observational study, Framingham Risk Score and Prospective cohort study.
The concepts of his Percutaneous coronary intervention study are interwoven with issues in Survival rate, Incidence and Retrospective cohort study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
